Vascular endothelial-targeted therapy combined with cytotoxic chemotherapy induces inflammatory intratumoral Infiltrates and inhibits tumor relapses after surgery

Neoplasia

Volumn 14, Issue 4, 2012, Pages 352-359

  Judy, Brendan F ^a   Aliperti, Louis A ^a   Predina, Jarrod D ^a   Levine, Daniel ^a   Kapoor, Veena ^a   Thorpe, Philip E ^b   Albelda, Steven M ^c   Singhal, Sunil ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; C44 ANTIBODY; CISPLATIN; MCH1N11; MONOCLONAL ANTIBODY; OKT 8; PHOSPHATIDYLSERINE; PHOSPHATIDYLSERINE ANTIBODY; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER RELAPSE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; DISEASE COURSE; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; GRANULOCYTE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LUNG CANCER; MOUSE; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT CANCER; SPLEEN CELL; T CELL DEPLETION; TUMOR VOLUME;

EID: 84860603546     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.12208     Document Type: Article

References (30)

1. Aliperti LA, Predina JD, Vachani A, and Singhal S (2011). Local and systemic recurrence is the Achilles heel of cancer surgery. Ann Surg Oncol 18, 603-607.
2. Pisters KM and Le Chevalier T (2005). Adjuvant chemotherapy in completely resected non-small-cell lung cancer. J Clin Oncol 23, 3270-3278.
3. Stuschke M and Pottgen C (2010). Chemotherapy: effectiveness of adjuvant chemotherapy for resected NSCLC. Nat Rev Clin Oncol 7, 613-614.
4. Kong B, Michalski CW, Friess H, and Kleeff J (2010). Surgical procedure as an inducer of tumor angiogenesis. Exp Oncol 32, 186-189.
5. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, et al. (2000). Genes expressed in human tumor endothelium. Science 289, 1197-1202.
6. Holmgren L, O'Reilly MS, and Folkman J (1995). Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1, 149-153.
7. Hadj Tahar A (2004). Bevacizumab for advanced colorectal cancer. Issues Emerg Health Technol, 1-4.
8. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G Jr, Lee JJ, Liu DD, Truong MT, et al. (2005). Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23, 2544-2555.
9. + T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res 65, 11752-11761.
10. Derose P, Thorpe PE, and Gerber DE (2011). Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment. Immunotherapy 3, 933-944.
11. Ran S, Downes A, and Thorpe PE (2002). Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 62, 6132-6140.
12. Ran S, He J, Huang X, Soares M, Scothorn D, and Thorpe PE (2005). Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin Cancer Res 11, 1551-1562.
13. Beck AW, Luster TA, Miller AF, Holloway SE, Conner CR, Barnett CC, Thorpe PE, Fleming JB, and Brekken RA (2006). Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice. Int J Cancer 118, 2639-2643.
14. He J, Yin Y, Luster TA, Watkins L, and Thorpe PE (2009). Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma. Clin Cancer Res 15, 6871-6880.
15. Huang X, Bennett M, and Thorpe PE (2005). A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice. Cancer Res 65, 4408-4416.
16. Gerber DE, Stopeck AT, Wong L, Rosen LS, Thorpe PE, Shan JS, and Ibrahim NK (2011). Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 17, 6888-6896.
17. Drucker L, Ciobotaro P, Kimchi O, Tohami T, Yarkoni S, Radnay J, Shapira H, and Lishner M (2003). Initial exposed phosphatidylserine levels correlate with cellular response to cytotoxic drugs. Eur J Haematol 70, 98-105.
18. 99mTc-annexin V. J Nucl Med 44, 92-97.
19. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, and Wu TC (1996). Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56, 21-26.
20. Ran S, Gao B, Duffy S, Watkins L, Rote N, and Thorpe PE (1998). Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 58, 4646-4653.
21. Broomfield S, Currie A, van der Most RG, Brown M, van Bruggen I, Robinson BW, and Lake RA (2005). Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res 65, 7580-7584.
22. Baldwin HS, Shen HM, Yan HC, DeLisser HM, Chung A, Mickanin C, Trask T, Kirschbaum NE, Newman PJ, Albelda SM, et al. (1994). Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31): alternatively spliced, functionally distinct isoforms expressed during mammalian cardiovascular development. Development 120, 2539-2553.
23. Yan HC, Juhasz I, Pilewski J, Murphy GF, Herlyn M, and Albelda SM (1993). Human/severe combined immunodeficient mouse chimeras. An experimental in vivo model system to study the regulation of human endothelial cell-leukocyte adhesion molecules. J Clin Invest 91, 986-996.
24. Haas AR, Sun J, Vachani A, Wallace AF, Silverberg M, Kapoor V, and Albelda SM (2006). Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res 12, 214-222.
25. Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, and Ellis LM (2010). Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol 11, 373-382.
26. He J, Luster TA, and Thorpe PE (2007). Radiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipids. Clin Cancer Res 13, 5211-5218.
27. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, and Albelda SM (2009). Polarization of tumor-associated neutrophil phenotype by TGF-β: "N1" versus "N2" TAN. Cancer Cell 16, 183-194.
28. Kousis PC, Henderson BW, Maier PG, and Gollnick SO (2007). Photodynamic therapy enhancement of antitumor immunity is regulated by neutrophils. Cancer Res 67, 10501-10510.
29. Schreiber K, Rowley DA, Riethmuller G, and Schreiber H (2006). Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments. Hematol Oncol Clin North Am 20, 567-584.
30. Stewart TJ, Greeneltch KM, Lutsiak ME, and Abrams SI (2007). Immunological responses can have both pro -and antitumour effects: implications for immunotherapy. Expert Rev Mol Med 9, 1-20.